Acyclic nucleoside analogues such as acyclovir (1, ACV; Wagstaff et al., 1994; Elion, 1983) or penciclovir (2, PCV; Boyd et al., 1987; Spruance et al., 1997) , are well known for the chemotherapy of human herpesviruses, e.g. herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), varicellazoster virus (VZV) or Epstein-Barr virus (EBV) (De Clercq, 1993) .
The synthesis of different cycloSal-phosphotriesters of the acyclic nucleoside analogues acyclovir (ACV), penciclovir (PCV) and T-penciclovir (T-PCV) as potential new lipophilic, membrane-soluble pronucleotides is described. The introduction of the cycloSal moiety was achieved by using reactive cyclic chlorophosphane reagents. In addition to the cycloSal-PCV monophosphate (MP) phosphotriesters, a second derivative bearing an acetyl group at the second primary alcohol function was prepared. In hydrolysis studies the cycloSal-ACVMPs showed the expected range of hydrolytic stability dependent on the substituent in the masking group (8-17 h). In contrast, the cycloSal-PCVMP derivatives exhibited a 11-to 15-fold increase in hydrolytic lability as compared to the corresponding cycloSal-ACVMP derivatives. We demonstrated that the free primary alcohol group is responsible for this rate acceleration because cycloSal-OAc-PCVMP, in which Introduction nator, as it does not contain the 3′-hydroxyl function necessary for the further chain elongation. However, ACVTP is also a potent HSV DNA polymerase inhibitor with a K i value for ACVTP versus the natural substrate dGTP of 0.1 µM (Elion, 1983) . The selective antiviral action of some antiherpesvirus agents like ACV is due to the preferential phosphorylation of the nucleoside into the acyclovir monophosphate (ACVMP) by a virus-encoded thymidine kinase (TK) (Vere Hodge et al., 1989) . On the other hand, ACV is not a particularly good substrate for HSV TK, and the rate of phosphorylation is reckoned to be slow (Field & Goldthorpe, 1995) . Moreover, resistant virus types are known. Acyclovir resistance may arise as a result of mutations in the genes encoding two enzymes: thymidine kinase (TK) and DNA polymerase (Fields, 1990) . The most common mutation is the selection of mutants deficient in TK activity or in mutants that induce TKs with altered substrate specificities. In such cases, acyclic nucleoside analogues in virus-infected cells are not converted into their monophosphates, which results in a loss of antiviral activity. The mode of antiviral action of PCV has been reported recently (Earnshaw et al., 1992) as well as a comparative study of the antiviral potencies of ACV and PCV (Weinberg et al., 1992) .
One possible strategy to improve the therapeutic potential of acyclic nucleoside analogues is the use of lipophilic prodrugs of the corresponding monophosphates (the pronucleotide approach). Different strategies have been developed in order to deliver nucleotides successfully into cells ( Jones & Bischofberger 1995; Meier, 1998) .
The aim of the present study was to investigate the properties of the different cycloSal-phosphotriesters 4-7 bearing ACV, PCV and its thymine analogue T-penciclovir (T-PCV, 3) as potential new lipophilic pronucleotides of the corresponding acyclic nucleoside monophosphates. The cycloSal moiety was chosen because we have already shown that nucleotides masked with this residue lead to intracellular delivery of the charged nucleotides, which are then effectively locked inside the cells (Meier et al., 1998b) . Donor-substituted cycloSal residues were chosen because in previous studies these resulted in the best structure-activity relationship (Meier et al., 1997a (Meier et al., -c, 1998a . Consequently, the 3-methyl-(4b-7b) and the 5-methyl substituted (4c) cycloSal derivatives were used in this study and unsubstituted cycloSal-triesters 4a, 5a and 7a were used for comparison ( Fig. 1) .
It should be added that other prodrug forms of the above-mentioned acyclic nucleoside analogues have been reported (Selby et al., 1984; Vere Hodge et al., 1989; Vere Hodge, 1993; Kim et al., 1994; Beutner, 1995) , but all these compounds have been designed to deliver the nucleosides and not the nucleotides. Only a few other attempts at pronucleotide design for ACVMP have been reported (Welch et al., 1995; Kumar et al., 1990; Farrow et al., 1990; Girardet, 1995; Abraham et al., 1997) but all these approaches failed to deliver ACVMP intracellularly in appreciable amounts. Only the acyclovir diphosphate dimyristoylglycerol approach showed some activity against acyclovir-resistant HSV (Hostetler et al., 1993) .
Materials and Methods: Chemistry
Compounds NMR spectra were recorded using Bruker AC 250, Bruker WM 400, Bruker AMX 400 and Bruker DMX 600 Fourier transform spectrometers. All 1 H and 13 C NMR chemical shifts (δ) are quoted in p.p.m. downfield from tetramethylsilane. The 31 P NMR chemical shifts are quoted in p.p.m. using H 3 PO 4 as the external reference. Coupling constants ( J) are given in Hz. The spectra were recorded at room temperature. Electrospray mass spectra were measured on a triple stage quadrupole mass spectrometer equipped with an electrospray source (TSQ 7000, Finnigan MAT, Bremen/Software ISIS 8.1). All UV spectra were recorded on a Varian Cary UV spectrometer. IR spectra were recorded on a Perkin-Elmer 1600 Series FT-IR spectrometer. Merck precoated 60 F 254 plates with a 0.2 mm layer of silica gel were used for thin layer chromatography (TLC). All preparative TLCs were performed on a chromatotron (Harrison Research, Model 7924T) using glass plates coated with 1 mm, 2 mm and 4 mm layers of Merck 60 PF 254 silica gel containing a fluorescent indicator. Analytical and semipreparative HPLC was done on a Merck-Hitachi HPLC system equipped with a LiChroCART 250-10 column containing reversed phase silica gel Lichrospher 100-10 RP 18 (10 µm) (Merck, Darmstadt, Germany). The resulting lyophilized products did not give useful microanalytical data most probably due to incomplete combustion of the compounds but were found to be pure by rigorous HPLC analysis using a gradient of 12-80% acetonitrile in water within 20 min, 0.6 ml/min (gradient A) or of 5-95% acetonitrile in water within 20 min, 0.5 ml/min (gradient B), high-field multinuclear NMR spectroscopy, and electrospray mass spectrometry. PCV was synthesized as described before (Harnden et al., 1987 (Harnden et al., , 1990 . The thymine analogue of PCV (T-PCV; 3) was prepared using the same synthetic approach. The differently substituted cyclic chlorophosphanes 8 were prepared as described before (Meier et al., 1998b) .
General procedure for the preparation of cycloSal-acyclovir monophosphates (cycloSal-ACVMPs) (4a-c) ACV was coevaporated twice with pyridine and the residue was suspended in a 2:1 mixture of dimethylformamide/tetrahydrofuran (DMF/THF). The solution was cooled to -20°C and di-i-propylethylamine (DIPEA) and the cycloSal-chlorophosphanes 8 were added dropwise. After TLC showed complete conversion of the starting material 1, the solution was cooled to -5°C, t-butylhy-droperoxide (TBHP) was added dropwise and stirred for 2 h at room temperature. The solvent was evaporated under reduced pressure. The crude products were purified by silica gel chromatography on a chromatotron using first a gradient of methanol in CH 2 Cl 2 and followed by a gradient of methanol in ethyl acetate.
cycloSal-acyclovir monophosphate (cycloSal-ACVMP) (4a)
Quantities: ACV 1 (1.0 equiv., 30.0 mg, 0.13 mmol), DMF/THF (2:1) 4.5 ml, di-i-propylethylamine (DIPEA) (5.0 equiv., 114 µl, 0.67 mmol), cycloSal-chlorophosphane 8a (1.5 equiv., 41.0 mg, 0.20 mmol), TBHP (5.0 equiv., 121 µl, 0.67 mmol). After chromatography, the triester 4a was isolated as a colourless foam (37.0 mg, 72%); R f : 0.54 (CH 2 Cl 2 /methanol 8:2 v/v); 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.6 (s, 1H, NH), 7.8 (s, 1H, H8), 7.4 (t, 1H, H4 arom. , J 7.8), 7.23 (dd, 1H, H6 arom. , J 7.9, J 1.6), 7.18 (dt, 1H, H5 arom. , J 7.4, J 1.2), 7.1 (d, 1H, H3 arom. , J 8.2), 6.5 (s, 2H, NH 2 ), 5.43 (dd, 1H, CH Abenzyl , J 14.5, J P 18.4), 5.35 (dd, 1H, CH Bbenzyl , J 14.5, J P 8.4), 5.32 (s, 2H, H1′), 4.2 (m, 2H, H5′), 3.7 (dt, 2H, H4′, J 3.9, J P 1.2); 13 C NMR (101 MHz, DMSO-d 6 ): δ 156.7 (C6), 153.9 (C2), 151.3 (C4), 149.5 ( J 6.1, C2 arom. ), 137.5 (C8), 129.7 (C5 arom. ), 125.9 (C4 arom. ), 124.3 (C6 arom. ), 120.9 ( J 10.7, C1 arom. ), 118.1 ( J 7.6, C3 arom. ), 116.5 (C5), 71.8 (C1′), 68.3 ( J 7.6, C benzyl ), 67.3 ( J6.1, C5′), 66.9 ( J 5.4, C4′); 31 
3-Methyl-cycloSal-acyclovir monophosphate (3-Me-cycloSal-ACVMP) (4b)
Quantities: ACV (1.0 equiv., 30.0 mg, 0.13 mmol), DMF/THF (2:1) 3.0 ml, di-i-propylethylamine (DIPEA) (2.5 equiv., 57.0 µl, 0.33 mmol), 3-methyl-cycloSalchlorophosphane 8b (2.5 equiv., 67.6 mg, 0.33 mmol), TBHP (2.5 equiv., 61.0 µl, 0.33 mmol). After chromatography the triester 4b was isolated as a colourless foam (43.0 mg, 80%); R f : 0.59 (CH 2 Cl 2 /methanol 8:2 v/v); 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.6 (s, 1H, NH), 7.8 (s, 1H, H8), 7.2-7.0 (m, 3H, CH arom. ), 5.4 (dd, 1H CH Abenzyl. , J 14.4, J P 17.6,), 5.32 (s, 1H, H1′), 5.31 (dd, 1H, CH Bbenzyl. , J 14.1, J P 9.9), 4.2 (m, 2H, H5′), 3.6 (m, 2H, H4′), 2.2 (s, 2H, H1′); 13 C NMR (63 MHz, DMSO-d 6 ): δ 156.9 (C6), 154.1 (C2), 151.1 (C4), 148.2 (C2 arom. ), 137.8 (C8), 131.0 (C4 arom. ), 126.9 (C3 arom. ), 124.1 (C5 arom. ), 123.7 (C6 arom. ), 121.1 (d, C1 arom. , J P 9.5), 116.7 (C5), 71.9 (C1′), 68.5 (d, C benzyl , J P 6.7), 67.5 (d, C5', J P 5.7), 67.0 (d, C4′, J P 5.7), 15. 
5-Methyl-cycloSal-acyclovir monophosphate (5-Me-cycloSal-ACVMP) (4c)
Quantities: ACV (1.0 equiv., 60.0 mg, 0.27 mmol), DMF/THF (2:1) 4.5 ml, di-i-propylethylamine (DIPEA) (2.5 equiv., 114 µl, 0.67 mmol), 5-methyl-cycloSalchlorophosphane 8c (2.5 equiv., 135.2 mg, 0.67 mmol), TBHP (2.5 equiv., 121 µl (0.67 mmol). After chromatography the triester 4c was isolated as a colourless foam (62.0 mg, 64%); R f : 0.59 (CH 2 Cl 2 /methanol 8:2 v/v); 1 H NMR (250 MHz, DMSO-d 6 ): δ 10.6 (s, 1H, NH), 7.8 (s, 1H, H8), 7.13 (d, 1H, H4 arom. , J 8.2), 7.0 (d, 1H, H6 arom. , J 1.2), 6.9 (d, 1H, H3 arom. , J 8.5), 6.5 (s, 2H, NH 2 ), 5.4 (dd, 1H, CH Abenzyl , J 14.7, J P 19.8), 5.32 (s, 2H, H1′), 5.29 (dd, 1H, CH Bbenzyl ,J 14.9, J P 8.9), 4.2 (dq, 2H, H5′, J 3.7), 3.6 (t, 2H, H4′, J 3.7), 2.3 (s, 3H, CH 3 ); 13 C NMR (63 MHz, DMSO-d 6 ): δ 154.0 (C6), 151.5 (C2), 147.6 (C4), 147.4 (d C2 arom. , J P 6.7,), 137.7 (C8), 133.7 (C5 arom. ), 130.1 (d, C4 arom. , J P 1.9), 126.1 (C6 arom. ), 120.5 (d, C1 arom. , J P 9.5), 118.0 (d, C3 arom. , J P 9.5), 116.6 (C5), 71.9 (C1′), 68.4 (d, C benzyl , J P 6.7), 67.4 (d, C5′, J P 6.7), 66.9 (d, C4′, J P 5.7), 20. 
Di
PCV (1.0 equiv., 285 mg, 1.10 mmol) was suspended in 20.0 ml pyridine at room temperature under argon atmosphere. To this suspension, t-butyldimethylsilylchloride (TBDMSCl; 2.2 equiv., 350 mg, 2.30 mmol) was added and subsequently stirred for 48 h. The mixture was extracted with water and the combined organic layers were dried using sodium sulphate. The solvent was evaporated under reduced pressure to yield 396 mg [75%, R f : 0.31 (CH 2 Cl 2 /methanol 9:1 v/v)] of a colourless compound. This intermediate was redissolved in pyridine, dimethoxytritylchloride (DMTrCl, 1.1 equiv., 402 mg, 1.20 mmol) and dimethylaminopyridine (DMAP, 0.11 equiv., 12.5 mg, 0.12 mmol) were added at room temperature and stirred for 24 h. The solution was extracted with a saturated solution of sodium hydrogen carbonate. The combined organic layers were dried (sodium sulphate) and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography on a chromatotron using a gradient of methanol in CH 2 Cl 2 . After evaporation of the solvent, product 9 was isolated as colourless foam (636 mg, 75%). R f : 0.59 (CH 2 Cl 2 /methanol 9:1 v/v); 1 H NMR (250 MHz, CDCl 3 ): δ 7.4-7.1 (m, 10H, DMTr-H), 6.8 (m, 4H, DMTr-H), 3.7 (s, 8H, H1′, 2×OCH 3 ), 3.5 (m, 4H, H4′), 1.9 (m, 1H, H3′), 1.5 (m, 2H, H2′), 0.9 (s, 18H, H3′′), 0.04 (s, 12H, H1′′); 13 C NMR (63 MHz, CDCl 3 ): δ 158.3 (C6, C D ), 151.0 (C2), 150.7 (C4), 142.4 (C E ), 137.4 (C8), 136.6 (C A ), 130.0 (C A ), 128.6 (C G ), 127.9 (C F ), 126.7 (C H ), 117.5 (C5), 113.2 (C C ), 70.1 (C q -DMTr), 62.7 (C4′), 55.1 (OCH 3 ), 41.8 (C1′), 40.9 (C3′), 28.8 (C2′), 25.9 (C3′′), 18.2 (C2′′), -5.4 (C1′′); UV (CH 3 CN): λ max 203.5, 235.0, 277.5 nm, λ min 226.0, 270.5 nm.
(1.0 equiv., 600 mg, 0.78 mmol) was dissolved in 2.0 ml THF. To this solution, tetrabutylammonium fluoride (TBAF; 3.0 equiv., 525 mg, 2.30 mmol) was added at ambient temperature. After 24 h, the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography on a chromatotron using a gradient of methanol in CH 2 Cl 2 . After evaporation, product 10 was isolated as a colourless foam (420 mg, 97%). R f : 0.12 (CH 2 Cl 2 /methanol 9:1 v/v); 1 H NMR (250 MHz 
Bis
N-(Dimethoxytrityl)penciclovir 10 (1.0 equiv. 415 mg, 0.75 mmol) was dissolved in 5.0 ml pyridine. To this solution, DMTrCl (1.2 equiv., 304 mg, 0.92 mmol) and DMAP (0.12 equiv., 40.0 mg, 0.09 mmol) were added under argon atmosphere. After stirring for 24 h at ambient temperature, the solution was extracted with a saturated solution of sodium hydrogen carbonate. The combined organic layers were dried (sodium sulphate) and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography on a chromatotron using a gradient of methanol in CH 2 Cl 2 . Compound 11 was isolated after evaporation as colourless foam (280 mg, 44%). R f : 0.49 (CH 2 Cl 2 /methanol 9:1 v/v); 1 H NMR (250 MHz, CDCl 3 ): δ 7.8 (s, 1H, NH), 7.4-7.0 (m, 19H, 2×DMTr-H, H8), 6.9 (s, 1H, NH), 6.85 (d, 4H, DMTr-H, J 8.9), 6.6 (d, 4H, DMTr-H, J 8.9), 3.8 (s, 6H, OCH 3 ), 3.7 (s, 6H, OCH 3 ), 3.5 (s, 2H, H1′), 3.4 (d, 2H, H4′ A , J 7.9), 3.1 (m, 2H, H4′ B ), 2.2 (s, 1H, OH), 1.5 (s, 3H, H3′, H2′); 13 C NMR (63 MHz, CDCl 3 ): δ 158.8 (C6), 158.4 (C D ), 151.0 (C2), 150.7 (C4), 145.1 (C E ), 144.6 (C E ), 137.4 (C8), 135.9 (C A ), 135.8 (C A ), 130.0 (C F ), 129.9 (C B ), 128.6 (C G ), 128.0 (C F ), 127.8 (C G ), 127.3 (C H ), 126.8 (C H ), 117.5 (C5), 113.2 (C C ), 112.7 (C C ), 86.3 (C q -ODMTr), 69.9 (C q -ODMTr), 64.4 (C4′), 55.1 (OCH 3 ), 54.9 (OCH 3 ), 41.6 (C1′), 38.6 (C3′), 28.4 (C2′); UV (CH 3 CN): λ max 203.0, 236.0, 275.0 nm, λ min 225.0 nm.
T-Penciclovir (1.0 equiv., 342 mg, 1.5 mmol) was suspended in 30.0 ml acetonitrile. To this suspension, DMTrCl (1.05 equiv., 534 mg, 1.6 mmol), pyridine (1.1 equiv., 130 mg, 1.7 mmol) and DMAP (0.1 equiv., 18.0 mg, 0.09 mmol) were added under argon atmosphere. After stirring for 2 h at ambient temperature, the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography on a chromatotron using a gradient of methanol in CH 2 Cl 2 . Compound 12 was isolated after evaporation as colourless foam (347 mg, 44%). R f : 0.50 (CH 2 Cl 2 /methanol 9:1 v/v); 1 H NMR (250 MHz To this solution di-i-propylethylamine (DIPEA, 2 equiv.) was added dropwise and the reaction mixture was cooled to -20°C. At this temperature the cycloSal-chlorophosphanes 8a,b (2 equiv.) were added carefully under stirring. After complete addition of the phosphitylating reagents 8, the reaction mixture was warmed to room temperature with stirring. After 2 h, TLC showed complete conversion of the starting materials 11 or 12, respectively. The solution was again cooled to -5 °C and TBHP (2 equiv.) was added dropwise and stirring was continued for 2 h at room temperature. The mixture was con-centrated under reduced pressure and the residue was purified by silica gel chromatography on a chromatotron using gradients of methanol in CH 2 Cl 2 and secondly of methanol in ethyl acetate. After evaporation of the solvent, the products were isolated as colourless foam.
Part b: dedimethoxytritylation of the intermediate
was dissolved in a 2% benzene sulphonic acid solution (BSA; CH 2 Cl 2 /methanol 7:3 v/v) and stirred at ambient temperature for 1 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography on a chromatotron using 15% methanol in CH 2 Cl 2 (isocratic). After evaporation of the solvent, the target compounds 5a,b and 7a,b were further purified by semipreparative HPLC using 21% acetonitrile in water (isocratic; flow rate of 4 ml/min; UV detection 260 nm). After lyophilization, compounds 5a,b and 7a,b were isolated as colourless fluffy solids. (C4), 148.7 (C2 arom. ), 142.0 (C6), 130.6 (C4 arom. ), 126.9 (C5 arom. ), 125.3 (C6 arom. ), 121.8 (C1 arom. ), 119.0 (C3 arom. ), 109.6 (C5), 69.0 (CH 2benzyl ), 60.5 (C4′(2)), 45.7 (C4′(1)), 27.5 (C3'), 12.8 (CH 3 ); 31 P NMR (162 MHz, DMSO-d 6 ): δ -9.635, -9.662 (2 enantiomeric pairs of diastereomers); UV (CH 3 OH): λ max 278.5, 205.0 nm, λ min 250.5 nm; PC (log P): 1.92 (0.28); purity: 98% (gradient A). 
3-Methyl

3-Methyl-cycloSal-O-acetyl-penciclovir monophosphate (3-Me-cycloSal-OAc-PCVMP) (6b)
To a solution of 3-methyl-cycloSal-PCVMP 5b (1.0 equiv., 30.0 mg, 0.07 mmol) in 5 ml pyridine acetic acid anhydride (3.0 equiv., 21.4 mg, 0.21 mmol) was added at ambient temperature and stirred for 3 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (gradient of methanol in CH 2 Cl 2 ). After evaporation of the solvent, compound 6b was further purified by semipreparative HPLC using 21% acetonitrile in water (isocratic; flow rate of 4 ml/min; UV detection 260 nm). After lyophilization, triester 6b was iso- 
NMR hydrolysis study of 3-methyl-cycloSal-PCVMP (5b)
3-Methyl-cycloSal-PCVMP 5b (0.50 mg, 1.1 nmol) was dissolved in 1.0 ml d 6 -dimethylsulphoxide and 0.2 ml water in an NMR tube and stored for 5 days at 37°C. The chemical shift in the 31 P NMR spectrum was δ -9.07 and -9.09, identical with compound 5b. Then, 30 µl of TRISbuffer (tri(hydroxymethyl)methylammonium chloride; pH 8.8) in H 2 O was added and the NMR tube was stored for further 7 days at 37°C. 1 H NMR (600 MHz, DMSO-d 6 , H 2 O-suppression (60 dB): δ 7.69 (s, 1H, H8), 6.45 (s, 2H, NH 2 ), 3.98-3.93 (m, 4H, H4′), 3.77 (m, 2H, H1′), 1.66 (q, 2H, H2′, J 7.0), 1.63-1.59 (m, 1H, H3′); (signals of the cyclophosphate); 6.93, 6.91 (d, 1H, H6 arom. , J 7.1), 6.81, 6.79 (d, 1H, H4 arom. , J 6.4), 6.58, 6.57, 6.56 (t, 1H, H5 arom. , J 7.4) 
Materials and Methods: Virology
Cells and viruses
Vero cells (ATCC, CRL 1587) were cultivated in modified MEM on Hanks' basis supplemented with 10% heat-inactivated fetal bovine serum and antibiotics. HSV-1 Kupka isolated in 1962 by Dr R Benda (Prague, Czech Republic), from a patient with herpes labialis (Benda et al., 1972) was kindly provided by Dr J Rajcani (Bratislava). For the experiments, the virus was propagated in Vero cells. The TCID 50 of the cell-free virus suspension was 10 7 -10 8 /ml. The TKnegative strain (HSV-1/TK -) was obtained from Dr E De Clercq (Leuven, Belgium), with the reference number B2006 (De Clercq et al., 1986) and was originally described by Dubbs and Kit (1964) . It was propagated in rabbit testes primary cells achieving a concentration of 10 6.5 TCID 50 /ml in the cell-free supernatant.
Antiviral sceening assay
The antiviral evaluation of the ACV, PCV and T-PCV derivatives was carried out by means of the XTT-based tetrazolium reduction assay EZ4U (Biozol, Eching, Germany) described recently (Klöcking et al., 1995) . The method allows the determination of the inhibition of viral cytopathogenicity as well as substance-induced cytotoxic effects.
Briefly, 200 µl of a Vero cell suspension (10 4 cells/ml) was seeded into the wells of a 96-well flat-bottomed microtitre plate and incubated to confluence at 37°C in a humid atmosphere containing 1% CO 2 . Two days later, the growth medium was removed and graduated concentrations of the test substance in serum-free MEM were added. Cells were infected or not with 10 5 TCID 50 /ml HSV-1 and further incubated at 37°C for 120 h. After replacing the supernatant with medium lacking phenol red, 20 µl of the activated XTT substrate solution was added per well. The plates were incubated at 37°C for 3 h and, subsequently, absorbance at 492 nm was measured (reference wavelength 620 nm) in a microplate reader. Percentages of antiviral and cytotoxic activities of the test compounds were calculated according to Pauwels et al. (1988) .
Each experiment was performed in triplicate. The mean is representative for two or three independent experiments. Substance concentrations at half-maximum (EC 50 ) and 90% virus inhibition (EC 90 ) as well as half-maximum cytotoxic effectiveness (CC 50 ) were calculated from doseresponse curves by regression analysis.
Results
In principle, two different approaches are possible to yield Benda et al., 1972. the title compounds 4-7. The first approach introduces the cycloSal moiety by the use of cyclic chlorophosphanes 8a-c [reactive phosphorus(III) chemistry] as described previously (Meier et al., 1998b) . The second approach involves the use of the less-reactive corresponding phosphorylating reagents [phosphorus(V) chemistry] (Meier et al., 1998a ). In the approach described here only the first methodology was used owing to better yields of the final phosphotriesters.
For the preparation of the acyclovir-containing phosphotriester derivatives 4a-c, we started from ACV. First we thought that we should use a N 2 -protected derivative of ACV because (i) we wanted to exclude a possible side reaction to the reactive phosphorus(III) reagents 8 with the exocyclic amino group of the purine ring, and (ii) we wanted to increase the low solubility of ACV in organic sol- vents. Later we noticed that this is not necessary. Therefore, we treated a suspension of ACV in acetonitrile or a 2:1 mixture of DMF/THF directly with the phosphitylating reagents 8 to yield the intermediate phosphites and after oxidation with tert-butyl hydroperoxide (TBHP) the target triesters 4a-c in an overall yield of 60% ( Fig. 2a) .
No N 2 -modified side products were observed under these reaction conditions. Penciclovir (2) and its thymine analogue T-PCV (3) were prepared according to a synthesis described previously (Harnden et al., 1987) . Here, both acyclic nucleoside analogues have to be protected because both are bearing two identical primary alcohol functionalities in the side chain. Consequently, first we protected both hydroxy groups of PCV 2 as TBDMS-ethers, followed by DMTrCl reaction to block the exocyclic amino group (75% yield of 9). Subsequently, both hydroxy groups in 9 were deprotected by reaction with tetrabutyl ammonium fluoride (TBAF) in THF in 97% yield. The resulting N 2 -DMTr-protected intermediate 10 was then reacted with 1.2 equiv. of DMTrCl in pyridine in the presence of dimethylaminopyridine (DMAP) for 24 h to give N,O-DMTr-PCV 11 in 65% (Fig. 2b) . Analogously, T-PCV (3) was converted into O-DMTr-T-PCV 12 in 44% yield (Fig. 2c) . These compounds (11,12) were further reacted with the chlorophosphanes 8a,b and oxidized with TBHP as described above for ACV 1. Final DMTr-cleavage was achieved by treatment with a solution of 2% benzene sulphonic acid (BSA) in methylene chloride:methanol (7:3 v/v) for 1 h which gave the cycloSal-PCVMP and cycloSal-T-PCVMP derivatives 5a,b and 7a,b in 43% and 63% overall yield, respectively.
For reasons that will be discussed later, 3-methyl-cycloSal-PCVMP 5b was O-acetylated at the remaining hydroxy group to give 6b with acetic acid anhydride in pyridine in 82 % yield.
In the case of the PCV-and the T-PCV-containing cycloSal-phosphotriesters 5-7, we obtained, as expected, a diastereomeric mixture with respect to the stereochemistry at the P-atom. Furthermore, after modification of one of the two primary alcohol groups of PCV 2 or T-PCV 3, respectively, a carbon centre of asymmetry has been created at the C3-position. As at the P-atom, the reaction proceeded at the C3 atom without enantio-or diastereoselectivity. In contrast, the ACV-bearing phosphotriesters 4a-c were isolated as enantiomeric mixtures. After chromatographic purification, the cycloSal-compounds 4-7 were characterized by means of 1 H, 13 C, 31 P NMR, and UV spectroscopy as well as electrospray mass spectrometry (ESI, positive mode).
Owing to the mentioned stereochemical aspects, the cycloSal-(T)-PCVMP phosphotriesters 5-7 displayed two closely spaced signals in the 31 P NMR spectra (1:1 mixtures; -9.09 to -9.77 p.p.m.), corresponding to the presence of two enantiomeric pairs of diastereomers, resulting from mixed stereochemistry at the phosphorus centre and the mixed stereochemistry at C3 of the alkyl side chain. Similar diastereomeric splitting, and phosphorus coupling where appropriate, were noted in the H-decoupled 13 C NMR spectra. The purity of the cycloSal-phosphotriesters 4-7 was further checked by analytical HPLC analysis. In almost all cases the two expected peaks of the diastereomers overlapped completely. For the biological evaluation, small amounts of the cycloSal-derivatives triesters were additionally purified by semipreparative HPLC using acetonitrile/water eluents in order to be sure to eliminate any trace of the corresponding nucleoside analogues.
All compounds have been studied for their lipophilic properties [partition coefficients in n-octanol/water (PC values)] as well as for their hydrolytic stability in 25 mM isotonic sodium PBS, pH 7.3. For the hydrolysis experiments we proceeded as described before (Meier et al., 1998a,b) . The detected amounts of phosphotriester were normalized by an internal standard. Quantification of the The PC values, the half-lives (t 1/2 ) and the rate constants k are summarized in Table 1 . All compounds have been evaluated for their inhibition of HSV-1 and HSV-1/TKreplication in Vero cells. ACV (1), PCV (2) and T-PCV (3) were included as reference compounds. The biological data (EC 50 , EC 90 , CC 50 and MTC values) are summarized in Table 1 .
Discussion
As expected, the ACV-bearing cycloSal-phosphotriesters 4a-c selectively delivered ACVMP in the hydrolysis studies in isotonic sodium PBS, pH 7.3. Consequently, the mechanism of hydrolysis via the benzyl phosphodiester 13 should be the same as published before (Fig. 3; Meier et al., 1997a Meier et al., , 1998a .
The half-lives were found to be 7 h and 18 h. These t 1/2 values are exactly in the same range as the half-lives found for the corresponding cycloSal-AZTMP (Meier et al., 1998b) and cycloSal-d4TMP derivatives (Meier et al., 1998a) . Furthermore, the cycloSal-ACVMP derivatives 4 showed the expected correlation of the half-lives and the electronic properties of the substituents. Additionally, the determination of the partition coefficient (PC value) of 3methyl-cycloSal-ACVMP 4b gave a PC value of 1.2 (log P 0.08) which means that this compound possesses a higher solubility in the lipophilic phase (n-octanol) than in the aqueous phase. Although the other two phosphotriesters 4a and 4b exhibited PC values <1, they were >10-and >24fold more lipophilic than ACV. As found with the hydrolysis values, the trend in lipophilic properties was similar to that found with other cycloSal-nucleotides.
Surprisingly, cycloSal-PCVMP compounds 5a,b showed a pronounced decrease in half-life as compared to cycloSal-ACVMP triesters 4a,b: cycloSal-PCVMP 5a was 15-fold less stable than the corresponding unsubstituted cycloSal-ACVMP 4a, while 3-methyl-cycloSal-PCVMP 5b was 11fold less stable than the ACVMP triester 4b. The same effect was also observed for the corresponding T-PCVMP derivatives 7a,b. We assumed that the reason for this marked increase in hydrolytic lability could be either an assisting effect of the second, unprotected hydroxy group in the vicinity of the phosphate triester moiety or a direct nucleophilic attack of this primary alcohol residue at the phosphorus centre. The consequences are (i) still the formation of PCVMP in the former case (except the rate acceleration) and (ii) the formation of cyclic penciclovir monophosphate 14 (cPCVMP) via a six-membered ring intermediate (Fig. 4) .
In order to study the effect of the hydroxy group in triesters 5 and 7 we decided to block this group by acetylation. The resulting 3-methyl-cycloSal-O-acetyl-PCVMP triester 6b was subsequently hydrolysed using the same conditions as before (isotonic PBS, pH 7.3). As shown in Table 1 , this new derivative 6b again showed a half-life comparable with that of the corresponding acyclovir triester 4b. This experiment clearly proves that the hydroxy group in 5 and 6 is responsible for the rate acceleration discussed above. In order to identify the hydrolysis product of the chemical hydrolysis of 3-methyl-cycloSal-PCVMP 5b, two experiments were conducted. A 31 P NMR experiment was carried out by solubilizing the triester in a DMSOd 6 /water mixture containing small amounts of Tris buffer, pH 8.8. After complete hydrolysis, a proton-coupled 31 P NMR spectrum was recorded. From the coupling pattern of the phosphorus signal at -4.5 p.p.m. (a singlet in the decoupled mode) it became apparent that the hydrolysis of 5b did not lead to the desired PCVMP but to a product which showed a quintet in the proton-coupled mode (data not shown). We have shown before that monophosphates will split into a triplet in the proton-coupled mode of the 31 P NMR spectrum (Meier et al., 1997a) . Two further possible products are (i) the benzyl nucleoside phosphodiester 13 but this intermediate should disappear during hydrolysis proceeds (Meier et al., 1997a) (Fig. 3) and (ii) the phenyl nucleoside phosphodiester but also in this case we should observe a triplet splitting in the spectra. Consequently, the multiplet observed strongly indicates the formation of the cPCVMP 14 (Fig. 4) (Meier et al., 1998a) . Hence, the NMR experiment and the mass spectrometric analysis strongly point to the formation of cPCVMP 14 (MW 315.2 g/mol) from the cycloSal-PCVMP derivatives 5a,b instead of the desired PCVMP.
In contrast to the unexpected hydrolytic behaviour, the effect of the cycloSal-modification to the lipophilicity was similar to that observed with the ACV triesters 4. The lipophilicity of PCV was increased 20-to 70-fold for 5a, 5b and 6b, respectively (Table 1 ). Nearly the same factors were obtained for the cycloSal-T-PCVMPs [21-fold (7a) and 43-fold (7b)].
The most important result from the biological evaluation of the described cycloSal-phosphotriesters is the high biological activity of the ACVMP-phosphotriesters 4 particularly against the thymidine kinase-deficient virus strain. As can be seen in Table 1 , all three derivatives showed EC 50 values in the same range as ACV in wildtype virus strain HSV-1-infected Vero cells. Much more important is the retention of this antiviral activity in thymidine kinase-deficient virus (HSV-1/TK -)-infected Vero cells. Although the unsubstituted and the 5-methylsubstituted cycloSal-ACVMP triesters 4a,c, respectively, have slightly reduced activity as compared to the wild-type virus, the activity is still 34-fold higher as compared to ACV 1. A further threefold increase in activity was detected for the 3-methyl-cycloSal-ACVMP derivative 4b as compared to 4a and 4c, which means a 113-fold higher antiviral activity with respect to ACV. Particularly, compound 4b proves that the cycloSal-compounds seem to be completely independent of the intracellular activation by the viral TK (efficient viral TK bypass) and that the triesters selectively deliver intracellularly ACVMP in Vero cells. The high efficacy of the cycloSal-ACVMP triesters is also shown in the EC 90 values of the compounds (Table 1) . The EC 90 value of the 3-methyl derivative 4b is only 1.3fold higher than its EC 50 value. Against HSV-1/TKall triesters 4 exhibited EC 90 values that were 31-to 136-fold lower compared with that of to ACV. To the best of our knowledge, this is the first example of an ACVMP delivery pronucleotide system against HSV-1 and HSV-1/TK -. Moreover, as shown in Table 1 , the cycloSal-triesters 4 exhibited no increase in cytotoxicity as compared to the parent nucleoside ACV (CC 50 >128 µg/ml). This is also reflected in the identical maximum tolerated concentrations (MTC values, i.e. the highest substance concentra-tion that does not cause microscopically visible cell alterations in non-infected cells) of triesters 4 as compared to ACV.
Compared with the results reported here, the previously described bisSATE-ACVMP compounds show lower activity against the wild-type virus as compared with ACV and this activity was almost completely lost in HSV-1/TK --infected MRC-5 cells (Girardet, 1995) . Furthermore, the amino acid phosphomonoester amidates of acyclovir failed to deliver ACVMP and were devoid of any biological activity against ACV-sensitive and ACVresistant HSV-1 isolates (Abraham et al., 1997) .
In contrast to the successful delivery of ACVMP into Vero cells, the cycloSal-(T)-PCVMP triesters 5-7, respectively, exhibited only very low if any antiviral activity against the above-mentioned viruses. This failure of antiviral activity can be explained by the intracellular or even extracellular (keeping in mind the very short half-lives) release of c(T)PCVMP (e. g. 14) , respectively. The failure of the O-blocked 3-methyl-cycloSal-PCVMP 6b could be due to a fast intra-or extracellular de-esterification by carboxyesterases which would again lead to compound 5b. It should be added that in contrast to PCV 2, its thymine counterpart T-PCV was, like the triesters 7a,b, devoid of any antiviral effect.
From the present work, it is obvious that the cycloSal-ACVMP derivatives 4a-c are potent inhibitors of HSV-1 infection in Vero cells. Most striking is the retention of antiviral activity in HSV-1/TK --infected Vero cells showing again the nucleotide delivery concept from this type of pronucleotides and furthermore proving a successful bypass of virus-encoded HSV-1 TK. These results prove that the pronucleotides described are possible candidates for the treatment of ACV-resistant virus infections. Furthermore, the results presented point out that the biological activity obtained with antiretroviral (anti-HIV) pronucleotides, e.g. cycloSal-d4TMP (Meier et al., 1998a) or cycloSal-ddAMP (Meier et al., 1997b) are entirely transferable to the DNA virus HSV. The concept, on the other hand, is not suitable for intracellular delivery of PCVMP from the corresponding phosphotriester derivatives 5. NMR and mass spectrometric studies strongly suggest the formation of cPCVMP 14 from the phosphotriesters 5. This explains the failure of nucleotide delivery in this case. The same should be the case for the cycloSal-T-PCVMP compound. However, in this special example it has to be proven whether T-PCVMP would act as an efficient DNA polymerase inhibitor. Clearly, further studies will be necessary in order to apply the cycloSal-concept also to nucleoside analogues as PCV or T-PCV.
